ANN ARBOR, Mich., July 27 /PRNewswire-FirstCall/ -- Adeona
Pharmaceuticals, Inc., (Amex: AEN), announced today that
Julie A. Caudill, B.B.A., has been
appointed Vice President of Finance and Corporate Controller. Ms.
Caudill brings to Adeona more than 15 years of
biotechnology-related accounting and Securities and Exchange
Commission compliance experience.
For the past 15 years, Ms. Caudill served in a variety of
financial reporting positions at Aastrom Biosciences, Inc., a
publicly-traded biotech company developing autologous cellular
therapies. Her most recent position at Aastrom was Corporate
Controller and Corporate Secretary. She has experience in financial
reporting, internal and external audit management, budget planning
and control, treasury operations, and stock option reporting. Prior
to Aastrom, Ms. Caudill served as Accounting Manager at KMS
Industries, Inc., and Senior Accountant at Gelman Sciences, Inc.
She earned her Bachelor of Business Administration from
Eastern Michigan University.
"We are excited to have attracted a financial person of Julie's
experience, integrity and character to our company," stated
James S. Kuo, M.D., M.B.A., Adeona's
Chief Executive Officer. "Given our multiple clinical trials
underway and a growing clinical reference laboratory business, it
was critical for us to strengthen our internal financial reporting
expertise with a high caliber individual like Julie."
About Adeona Pharmaceuticals, Inc.
Adeona (AMEX: AEN) is a pharmaceutical company developing new
medicines for serious central nervous systems diseases. Adeona's
primary strategy is to in-license clinical-stage drug candidates
that have already demonstrated a certain level of clinical efficacy
and develop them to an inflection point in valuation resulting in a
significant development and marketing collaboration. Further
information on the company is available at www.adeonapharma.com
This release includes forward-looking statements on Adeona's
current expectations and projections about future events. In some
cases forward-looking statements can be identified by terminology
such as "may," "should," "potential," "continue," "expects,"
"anticipates," "intends," "plans," "believes," "estimates," and
similar expressions. These statements are based upon current
beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict
and include statements regarding our growing clinical reference
laboratory business. The forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those set forth or implied by any forward-looking
statements. Important factors that could cause actual results to
differ materially from those reflected in Adeona's forward-looking
statements include, among others, a failure of our clinical
trials to achieve desired results, a failure of our clinical
reference laboratory to continue to grow or a failure to
successfully commercialize products and other factors described in
Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the
SEC. The information in this release is provided only as of the
date of this release, and Adeona undertakes no obligation to update
any forward-looking statements contained in this release on account
of new information, future events, or otherwise, except as required
by law.
SOURCE Adeona Pharmaceuticals, Inc.